Default company panoramic image
Logo

MyFamily First Technologies

Roche purchased similar capabilities for $200M - Bloodhound. Our ‘Puppy’ has been vetted by a global leader and the first right of refusal has been purchased.

  • Stage Full Product Ready
  • Industry Healthcare Services
  • Location Houston, TX, USA
  • Currency USD
  • Founded December 2012
  • Employees 3
  • Website myfamilyfirsttechnologies.com

Company Summary

Rapid evaluation of patients will lower the overall healthcare delivery cost, provide greater independence for age-related diseases, and promotes active lifestyles. In 2013 Roche invested $200M in the Bloodhound prototype for hospital blood diagnostics. MyFamily First Technologies advanced those capabilities, now offering point-of-care testing (POCT) at a disruptively low cost/high margin, nicknamed the Puppy. All from a single finger stick.

Team

  • Default avatar
    Glenn Spaulding, M.S., M.D.
    CEO

    The CEO has 30 years experience successfully advancing companies through all stages: from concept to IPO. We have decades in combined successes advancing clinical products through all stages: from idea to production and sales. Our management has launched similar products through fortune 100 companies to global sales.

Advisors

  • Default avatar
    tbd
    Lawyer
    Unconfirmed
    Default avatar
    tbd
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Clear Lake Medical Foundation
    Unconfirmed